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Abstract
Background: Though an important percentage of patients with chronic hepatitis C virus (HCV) undergoing interferon (IFN)
therapy develop depressive symptoms, the role of the IFN system in the pathogenesis of depressive disorders is not well
understood.
Methods: 50 patients with HCV infection were treated with standard combination therapy (pegylated IFN-a2a/ribavirin).
IFN-induced gene expression was analyzed to identify genes which are differentially regulated in patients with or without
IFN-induced depression. For validation, PBMC from 22 psychiatric patients with a severe depressive episode (SDE) and 11
controls were cultivated in vitro with pegylated IFN-a2a and gene expression was analyzed.
Results: IFN-induced depression in HCV patients was associated with selective upregulation of 15 genes, including 6 genes
that were previously described to be relevant for major depressive disorders or neuronal development. In addition,
increased endogenous IFN-production and selective hyper-responsiveness of these genes to IFN stimulation were observed
in SDE patients.
Conclusions: Our data suggest that selective hyper-responsiveness to exogenous (IFN therapy) or endogenous (depressive
disorders) type I IFNs may lead to the development of depressive symptoms. These data could lead to the discovery of novel
therapeutic approaches to treat IFN-induced and major depressive disorders.
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Introduction
Chronic hepatitis C virus (HCV) infection is a major cause for
liver-related morbidity and mortality affecting approximately
170 million individuals worldwide. Around 70% of patients
develop histological evidence of chronic liver disease, which may
ultimately lead to liver cirrhosis and hepatocellular carcinoma [1].
In recent studies using pegylated interferon (IFN)-a2 in combina-
tion with ribavirin response rates for genotype 1 patients were
approximately 40–50% while patients with genotype 2 or 3
respond in about 80–90% [2–4]. A major obstacle for this
combination therapy, however, is the development of depressive
side effects that is observed in 22–31% of patients [2–4].
There is an increasing body of evidence that point at depression
as an inflammatory disorder prompted by deregulated levels of
pro-inflammatory cytokines, such interleukin-1b, IL-6, tumor
necrosis factor-a, IFN-c and IFN-c-induced protein 10 (IP-10)
[5–9]. It is known that IFN-a is a pro-inflammatory innate
immune cytokine that causes high rates of depression in humans.
The IFN-a mediated depression has been widely reported in
patients treated for hepatitis B, hepatitis C and malignant
melanoma and can induce to suicidal behavior [7,8,10,11].
Despite the increasing significance of this phenomenon, the
molecular interactions underlying this outcome are poorly un-
derstood. Multiple mechanisms including immune, neurotrans-
mitter and neuroendocrine pathways have been associated with
IFN-a mediated depression, and a wide range of putative risk
factors are being proposed and studied at genetic, molecular and
behavioral levels. As cytokines affect the synthesis, release and
cellular reuptake of monoamines and their dysregulation affects
several central nervous system functions, it has been postulated
that some neurophysiologic changes that affect activity of the
noradrenergic and/or the serotonergic neuron system may occur
during IFN therapy [12–14]. It has been shown that IFN-a can
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38668promote the depletion of serotonin by inducing the activation of
indolamine 2,3 dioxygenase (IDO1), responsible of the conversion
of tryptophan to kynurenine (12, 14, 15), and plays a crucial role as
molecular mediator of inflammation-induced depressive-like be-
havior in mice [15–17]. Concomitantly, IFN-a may alter
dopamine metabolism by changes in kynurenic acid, a tryptophan
metabolite that can affect dopamine release, and decreased
concentrations of tetrahydrobiopterin (BH4) as an enzyme co-
factor for tyrosine hydroxylase, which is the rate limiting enzyme
in the synthesis of dopamine (13, 15). Moreover, it has been shown
that IFN-a is a potent inducer of mitogen activated protein kinase
(MAPK) signaling pathways [18], that have been reported to
activate monoamine transporters and thereby deplete their
synaptic concentrations [13,19]. Studies in experimental animals
have revealed that IFN-a, when injected into the ventricular
system, can suppress serotonin (5-HT) and dopamine levels in the
striatum, frontal cortex and midbrain [12,14]. IFN-a may also
indirectly stimulate the hypothalamic-pituitary-adrenal axis, which
is known to be overactive in depression, by inducing cytokines (e.g.
IL-6), that activate this system [20–22]. Interestingly, administra-
tion of IFN-a to non-human primates has been associated with
immune, neuroendocrine and behavioral responses similar to that
observed in humans. Thus, it has been found to increase plasma
adrenocorticotrophic hormone, cortisol and IL-6, to decrease
corticotrophin-releasing factor and to promote a depressive-like,
huddling behavior [23]. Concomitantly, most of these molecular
alterations are represented by genetic signatures, which have been
reported in a variety of studies relating the prevalence of genetic
polymorphisms on monoamine- and interleukin- related pathways
with the development of IFN-induced depression (i.e., IDO1,
serotonin receptor and transporter polymorphisms [24–27], and
IL-6 polymorphisms [24], reviewed in [28]). Some of them are
widely studied in case of idiopathic depression as well (reviewed in
[29]). The growing evidences about the role of exogenous IFN on
depression have promoted that genetic surveys extend towards the
study of the IFN-related pathways. Thus, polymorphisms in IFN
receptor alpha 1 have been proposed as a risk factor for the
development of depressive symptoms during IFN-a therapy [30].
Further studies in mice have suggested that systemic IFN-
a treatment may also have a direct effect by upregulating IFN-
stimulated genes (ISGs) in the brain with a profile very similar to
peripheral organs [31]. Until this point it was not clear, however,
which ISGs are directly or indirectly involved in the induction of
depression.
Therefore, we have studied in vivo the primary transcriptional
response to IFN-a in patients treated for chronic hepatitis C to
identify target genes that mediate the depressive side effects of
IFN-a. With the aim to conjugate both, idiopathic- and IFN-
derived-depression genetic background, the results were further




A total of 50 treatment naı ¨ve patients with chronic hepatitis C
that fulfilled standard inclusion criteria as described previously [3]
were included into this single-site prospective study (Table 1).
They were treated with pegylated IFN-a2a (Pegasys, Roche;
180 mg s.c. once weekly) in combination with oral ribavirin (body
weight , 75 kg: 1000 mg/d; body weight . 75 kg: 1200 mg/d)
for 12 months (HCV genotype 1/4, n=41/1) or 6 months (HCV
genotype 2/3, n=1/7), respectively.
22 psychiatric patients hospitalized for a severe depressive
episode (SDE) were prospectively analyzed to validate the target
genes in an independent cohort. The diagnosis of a SDE was
based on the psychiatric evaluation by a board-certified psychi-
atrist. The severity of depression was assessed using the 17-item
Hamilton Depression Rating Scale (HAMD-17) that is a common
tool in clinical trials [32]. A recurrent depressive disorder was
diagnosed in 17 patients (ICD-10: F33.2), one of them with
psychotic symptoms (ICD-10: F33.3), 3 patients had a bipolar
affective disorder with a severe depressive episode (ICD-10:
F31.4), and two patients a severe depressive episode (ICD-10:
F32.2).
All parts of study were approved by the local ethical committee
at the University Hospital of Essen. Patients from both patient
cohorts and relatives of the deceased gave their written informed
consent.
Diagnosis of Depression During IFN Therapy
Before IFN therapy all HCV patients filled out questionnaires
(Hospital Anxiety and Depression Scale (HADS) and Beck
Depression Inventory (BDI)) to quantify possible preexisting
depressive symptoms. Depression scores were measured three,
six and twelve months after IFN therapy. The structured
psychiatric interview Mini-DIPS was conducted in 47 patients
with known or suspected pre-existing psychiatric disorders by
a board-certified psychiatrist resulting in the diagnosis of previous
intravenous heroin abuse (n=8) and several psychiatric disorders
(Table 1) in 15 of the patients. Patients with schizophrenia were
treated with neuroleptic medication before and during IFN
therapy. Three patients received antidepressive medication before
initiation of therapy. Eleven patients developed moderate de novo
depressive symptoms and were treated with antidepressive
medication of citalopram 20 mg per day. Symptoms of depression
improved under this therapy and no patient discontinued IFN
therapy prematurely.
Isolation and in vitro Stimulation of PBMC
Blood samples were taken from healthy controls (n=11) or
patients hospitalized for a severe depressive episode (n=22). Then,
PBMC were isolated as previously described [33] and cultured for
16 h in the absence or presence of 100 U/mL pegylated IFN-a2a
followed by isolation of total RNA as described later. All
experiments were performed in triplicate under stringent endo-
toxin-free conditions.
Isolation of Total RNA from Peripheral Blood, Cultivated
PBMC
For in vivo gene expression analysis, peripheral blood was
collected directly into PAXgene Blood RNA Tubes (Becton
Dickinson, Heidelberg, Germany) and RNA was isolated using the
PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) according
to the instructions of the manufacturer.
For in vitro gene expression analysis, total RNA was isolated
from cultivated PBMC using Trizol (Invitrogen, Karlsruhe,
Germany) followed by a cleanup procedure using the RNeasy
Mini Kit and the RNase-Free DNase Set (both from Qiagen)
following the manufacturer’s protocol.
DNA Microarray Analysis
Double-stranded cDNA was synthesized from 20 mg of total
RNA using Superscript II (Gibco, Gaithersburg, MD) and an oligo
T-7-(dT)24 primer. cRNA was synthesized using a primer that
contained a T-7 RNA polymerase site that is labeled with biotin-
Endogenous and IFN-Induced Depression
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labeling kit (Enzo, Farmingdale, NY) following the manufacturer’s
protocol. Hybridizing, washing, antibody amplification, and
staining of probe arrays are performed according to the
instructions of the manufacturer. Experiments were performed
using human genomic microarrays (HG-U133A 2.0, Affymetrix,
Santa Clara, CA). GeneChip Operating Software (GCOS
v1.2.0.037, Affymetrix) was used to perform absolute analyses of
individual microarrays followed by comparison analyses between
individual off- an on-treatment samples. Data filtering was
performed using the Data Mining Tool software (DMT v3.1,
Affymetrix).
Real-time Detection Gene Expression with One-step RT-
PCR
In order to determine the gene expression levels of the
candidate ISGs, endogenous IFNs and TLRs one-step RT-PCR
with real-time detection was performed on the Rotor-Gene 2000
real-time amplification system (Corbett Research, Mortlake,
Australia). One-step RT-PCR was carried out with the Quanti-
Tect SYBR Green RT-PCR Kit (Qiagen) according to the
manufacturer’s instructions as described before [34]. Three house-
keeping genes b-actin (ACTB), tyrosine 3-monooxygenase/trypto-
phan 5-monooxygenase activation protein (YWHAZ), and b2-
microglobulin (B2M) were quantified for normalization of gene
copy numbers to the variable RNA amounts within the different
samples. For each gene data are shown as copy numbers
normalized to the number of ACTB transcripts in the sample.
Self-designed primers were used for ACTB, B2M, GBP1, IFIT1,
ISG15, MX1, STAT1, and YWHAZ (Table 2). For all other genes
commercial primers were used (QuantiTect Primer Assay,
Qiagen).
Statistical Methods
Prior to significance and prediction analyses the different chip
raw data were normalized by means of background adjustment
and quantile normalization using the RMAExpress v0.4.1 software
[35]. To identify genes which are differentially expressed in HCV
patients with or without IFN induced depression the Significance
Analysis of Microarrays (SAM v3.0) Excel add-in was used [36].
SAM computes repeated permutations of the data to determine if
the expression of any genes are significantly related to a given
response variable (i.e. before or after IFN treatment). The cut off
for significance is determined by a tuning parameter delta, chosen
to minimize the false positive rate.
Class prediction analysis was performed using the Prediction
Analysis for Microarrays (PAM v2.1) Excel add-in to identify genes
that best characterize each of two given classes (IFN induced
depression or no depression) using the nearest shrunken centroid
method [37].
Statistical analysis of the gene expression levels was performed
using the T-Test or Mann-Whitney test as appropriate using the
GraphPad Prism software (version 4.03). The null hypothesis was
rejected at the p#0.05 level.
Results
As described previously, 22% (11/50) of the HCV patients
treated with pegylated IFN-a2a and ribavirin developed de-
pressive side effects during therapy [3]. Development of depressive
side effects did not correlate with response to therapy, sex, age,
Table 1. Characteristics of the study participants.
HCV (n=50) SDE (n=22) Control (n=11)
Age [years], mean 6 SEM 43.62615.75 51.23638.60 36.22623.22
Female, n (%) 20 (40) 14 (60,9) 6 (54.6)
BMI [kg/m
2], mean 6 SEM 25.5962.51 25.3763.87 23.4263.68
ALT [U/L], mean 6 SEM 97.226145.45 25.52640.05 –
HCV genotype 1, n (%) 41 (82) – –
HCV load [IU/mL], mean 6 SEM 1.16 E+0662.58 E+11 – –
SVR, drop, n (%) 19 (38) / 4 (8) – –
Inflammation grade 0,1,2,3,4, n.d., n (%) 2 (4), 22 (44), 17 (34), 1 (2), 1 (2) ,7 (14) – –
Fibrosis stage 0,1,2,3,4, n.d., n (%) 6 (12), 15 (30), 11 (22), 7 (14), 4 (8), 7 (14) – –
De novo depression, n (%) 11(22), 39 (78) – –
Pre-existing psychiatric disorder, n (%) 9 (18) – –
Psychotropic drugs use, n (%) 8 (16) – –
Pre-existing heroin abuse, n (%) 4 (8) – –
Heroin abuse, n (%) 2 (4) – –
Acute SDE, n (%) – 2 (6.7) –
RDD + acute SDE, n (%) – 18 (78.3) –
RDD + acute SDE + psych. symptoms, n (%) – 1 (4.4) –
Bipolar disorder + acute SDE, n (%) – 3 (13.0) –
HAMD-17, mean 6 SEM – 23.1163.15 –
Abbreviations: HCV = hepatitis C virus, BMI = body mass index, ALT = Alanine aminotransferase, SVR = sustained viral response, drop = study drop-out, HAMD=
Hamilton Depression Rating Scale, Psych. = psychotic, RDD = recurrent depressive disorder, SDE = severe depressive episode, SEM = standard error of the mean, n.d.
= not determined.
doi:10.1371/journal.pone.0038668.t001
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therapy or response to therapy (data not shown).
To identify candidate genes which mediate the depressive side
effects of IFN-a, microarray analysis of the primary transcriptional
response to IFN-a was performed in those 11 patients that
developed depression during therapy in comparison to 11
randomly chosen HCV patients that did not experience such side
effects. Using significance and class prediction analysis, a total of
15 genes were identified that were selectively hyper-responsive to
exogenous IFN-a in patients that developed depressive side effects
(Table 3). In addition, considering the previous reported
association with IFN-related depression [13,18,19,38], the micro-
array results of IP-10 and IDO1 underwent statistical analysis.
Although a trend towards an increased expression was observed,
changes were not statistically significant which may be due to the
small sample population and the very early time point (12h)
studied after IFN injection (data not shown).
To validate these candidate genes in different patient popula-
tions under different experimental conditions, the in vitro response
to pegylated IFN-a2a was studied in a cohort of 22 psychiatric
patients that were hospitalized for a SDE. Compared to healthy
controls, pegylated IFN-a2a led to a significantly higher induction
of GCH1, TOR1B (Figure 1A), DYNLT1 and DISC1 (Figure 1B)
while there was a trend towards higher induction for MEF2A and
ST3GAL5 (data not shown). No difference was observed for
classical ISGs like MX1 or ISG15 (Figure 1C) as well as IFIT1 and
IFI16 (data not shown) suggesting that there is a selective rather
than a general hyper-responsiveness to type I IFNs in these
patients.
When baseline levels of ISGs were studied in patients with SDE
after 24h without additional stimulation, a significant upregulation
Table 2. Self-designed primers used for quantitative real time RT-PCR.
Gene Accession Number Forward Primer (592 239) Reverse Primer (592 239)
ACTB BC016045 TCCCTGGAGAAGAGCTACGA AGCACTGTGTTGGCGTACAG
B2M NM_004048 CAAATTCTGCTTGCTTGCTTT TGGAGCAACCTGCTCAGATAC
GBP1 NM_002053 TTGCTGAAAGAGCAAGAGAGG TGGTTAGGGGTGACAGGAAG
IFIT1 NM_001548 GCCCAGACTTACCTGGACAA GGTTTTCAGGGTCCACTTCA
ISG15 NM_005101 TGTCGGTGTCAGAGCTGAAG AGAGGTTCGTCGCATTTGTC
MX1 NM_002462 AGCCACTGGACTGACGACTT GAGGGCTGAAAATCCCTTTC
STAT1 NM_007315 CCGTTTTCATGACCTCCTGT TGAATATTCCCCGACTGAGC
YWHAZ NM_145690 ATCCATGCTGTCCCACAAA TGGCCACCTCAAGATGAAA
Abbreviations: RT-PCR = reverse transcription polymerase chain reaction.
doi:10.1371/journal.pone.0038668.t002
Table 3. Genes associated with interferon-induced depression.
Gene Full gene name / functional association Transcript ID
DISC1 disrupted in schizophrenia 1 / alterations of hippocampal structure and function, neurite outgrowth
and cortical development, neuron migration, neuroblast proliferation
NM_018662
DYNLT1 dynein, light chain, Tctex-type 1 / hippocampal neuron development (e.g. neurite sprouting, axon
specification, dendritic elaboration)
NM_006519
GBP1 guanylate binding protein 1, interferon-inducible / ISG NM_002053
GCH1 GTP cyclohydrolase 1 / bipolar disorder, depression, anxiety, dopamine biosynthesis NM_000161
GLRX glutaredoxin (thioltransferase) / ISG NM_002064
MEF2A MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) / neuronal
differentiation, suppression of hippocampal excitatory synapse number, postsynaptic differentiation
NM_005587
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) / ISG NM_002800
RBCK1 RanBP-type and C3HC4-type zinc finger containing 1 / ISG NM_006462
RTP4 receptor (chemosensory) transporter protein 4 / ISG NM_022147
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 / apoptosis in mouse hippocampal cell lines;
Amish infantile epilepsy syndrome; ganglioside biosynthesis
NM_003896
STAT1 signal transducer and activator of transcription 1 / ISG NM_007315
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 / ISG NM_003810
TOR1B torsin family 1, member B (torsin B) / idiopathic dystonia, recurrent major depression; widespread
neuronal expression; regulation of neurotransmitter release
NM_014506
UBE2L6 ubiquitin-conjugating enzyme E2L 6 / ISG NM_004223
ZNF200 zinc finger protein 200 / ISG NM_003454
Abbreviations: ISG = interferon stimulated gene.
doi:10.1371/journal.pone.0038668.t003
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was observed (Figure 2A) suggesting that there is an increased
production of endogenous IFNs in these patients. To test this
hypothesis, we assessed the in vivo baseline levels of the most
abundant IFN-a subtypes (IFN-a1 and -a2), IFN-b and IFN-c by
quantitative RT-PCR (Table 4, Figure 2B). The most striking
finding was a significant upregulation of IFN-b production in
patients with SDE compared to controls. Also, there were
increased mRNA levels of IFN-a1 and IFN-a2 and a trend
towards higher levels of IFN-c suggesting a broad activation of
type I and II IFN production in SDE patients. Interestingly, IFN-
b expression was profoundly enhanced in HCV patients before
therapy consistent with a direct stimulation by HCV through the
Toll-like receptor (TLR) system (Table 4). IFN-c mRNA levels
were elevated in HCV patients that could be explained by
activation of the PBMC-derived immunity while no significant
changes in IFN-a mRNA levels were observed.
Type I and II IFNs were significantly upregulated in depressive
individuals confirming the results from the peripheral blood of
SDE patients (Table 4). Interestingly, we also found an upregula-
tion of TLR3 and TLR7 that function as sensors of the innate
immune system for viral structures in particular, reviewed in [39].
In HCV-positive individuals a significant upregulation of IFN-
b was observed (p,0.005) compared to HCV-negative individuals.
Discussion
Determining the role of genetic vulnerability to harmful side
effects is becoming a crucial issue in order to progress toward
individualized drug therapy with successful outcome. A major
obstacle of IFN therapy for chronic hepatitis C is that about
a quarter of these patients will develop depressive side effects that
can even lead to suicide in some cases [2,3]. The pathophysiology
of IFN-induced depression, however, is not well understood. Most
of the molecular dysregulations observed in IFN-related de-
pression are similar to those described for idiopathic depression,
suggesting the existence of common pathways to both disorders. In
fact, the monocyte-T-lymphocyte hypothesis of mayor depression
predicts an immune system activation subjacent to the pathophys-
iology of major depressive disorder [40], and the association of the
depressive symptoms with an increased production of pro-
inflammatory cytokines [5–8] may indicate that they are the
result of a maladaptive response to immune activation. Pegylated
IFN-a and ribavirin therapy, as source of an artificial pro-
inflammatory cytokine, has been related to the risk of develop
depressive behavior by affecting the monoamine and cytokine
balance, but a common genetic background with idiopathic
depression is not yet elucidated. Our data suggest that the
development of depressive side effects during therapy with
pegylated IFN-a and ribavirin for chronic hepatitis C is associated
with a selective hyper-responsiveness of the IFN system. This leads
to the disproportional upregulation of 15 genes including 6 genes
that were previously reported to be relevant for recurrent major
depression or neuronal development in the brain. The relevance of
these genes was validated in a separate cohort of psychiatric
patients hospitalized for a severe depressive episode by analyzing
the in vitro induction of these ISGs by pegylated IFN-a. In these
cohorts, we were also able to demonstrate enhanced basal
production of endogenous IFNs, which may contribute to the
cytokine levels dysregulation. The 15 target genes include
DYNLT1, GCH1, TOR1B, DISC1, MEF2A and ST3GAL5 that to
date were never related to an IFN-a regulation while all of them
have been described in association with brain development or
depression. TOR1B, which shows immunoreactivity in all subfields
of the hippocampus [41], is homologue to TOR1A (alternative
name: DYT1), is associated with early-onset recurrent major
depression and is involved in the regulation of dopamine release
[42]. DYNLT1 (alternative name: TCTEL1) plays a key role in
multiple steps of hippocampal neuron development such as neurite
sprouting, axon specification and dendritic elaboration [43].
MEF2A is also involved in neuronal differentiation and post-
synaptic differentiation [44–46]. DISC1 plays a role in neurite
outgrowth and cortical development and contributes to alterations
of hippocampal structure and function [47,48]. Furthermore,
genetic analyses revealed an association with schizophrenia and
major depression [49–52]. ST3GAL5 is involved in neuronal
apoptotic cell death in mouse hippocampal cell lines [53]. Finally,
GCH1 is the rate-limiting enzyme in BH4 biosynthesis, an essential
cofactor required by the aromatic amino acid hydroxylase and
nitric oxide synthase which are in turn the rate-limiting enzymes in
dopamine and serotonin biosynthesis. Interestingly, it has already
been shown that different IFN types, including pegylated-IFN
forms, are able to induce GCH1 activation with the subsequent
increase of BH4 and its precursor neopterin, released from
monocytes and macrophages [54,55], which has been widely used
as a pharmacodynamic marker in the evaluation and optimization
of IFN therapy [56,57]. Even more, several authors have lately
reported that IFN-a therapy impairs phenylalanine metabolism in
HCV infected individuals [58,59], suggesting that behavioural side
effects may be associated with the modulation of BH4 levels, thus
affecting dopamine, serotonin and noradrenaline biochemistry.
Clinically, alterations of GCH1 activity has been associated with
bipolar disorders, depression, anxiety, dystonia and deafness
[60,61]. The hippocampus is one of several limbic brain structures
implicated in the pathophysiology and treatment of mood
disorders. Recently, it has been suggested that depression may
have a neurogenic origin as loss of neurons in the adult
hippocampus is observed and neurogenesis is required for the
actions of antidepressants [62,63]. Furthermore, it has been
demonstrated that exogenous administration of IFN-a suppressed
neuronal proliferation via proinflammatory cytokines IL-1b and
TNF-a in the hippocampus of adult rats [64]. Previous studies
revealed that the exposition to these cytokines induce depressive
symptoms in humans and depression-like behavior in animals.
Latter findings even related specifically increased plasma levels of
the mentioned cytokines to the cause of severe depressive
symptoms in HCV patients [65]. Our data suggest that IFN-
a may interfere with these processes through modulation of the
target genes identified in this study.
Patients with chronic HCV infection often report fatigue,
depressive mood, impaired cognitive functions, and reduced
quality of life [66–68]. As these symptoms do not correlate with
Figure 1. Enhanced IFN-mediated induction of selective ISGs in HCV patients with IFN-induced depression (in vivo) and psychiatric
patients with a severe depressive episode (SDE, in vitro). Total RNA was isolated from peripheral blood of hepatitis C virus (HCV) infected
patients with (n=11, ‘‘HCV-D’’) or without (n=11, ‘‘HCV-N’’) IFN-induced depression 12 hours before and 12 hours after the first injection of
pegylated IFN-a2a. Expression of IFN stimulated genes (ISGs) was analyzed by quantitative RT-PCR (panel A: GCH1, TOR1B; panel B: DYNLT1, DISC1;
panel C: MX1, ISG15). To validate the data in an independent cohort, PBMC were isolated from 11 healthy controls (‘‘co-N’’) and 22 patients
hospitalized for a SDE (‘‘co-D’’) and stimulated with 100 U/mL pegylated IFN-a2a in vitro for 16 h followed by isolation of total RNA. Data are shown
as box plots (range, 25% and 75% percentile, mean).
doi:10.1371/journal.pone.0038668.g001
Endogenous and IFN-Induced Depression
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38668severity of liver disease, hepatic encephalopathy, or history of
intravenous drug use [66], it has been speculated that HCV itself
may cause these alterations. This is supported by the fact that
HCV RNA is detectable in the brain [69] or in cerebrospinal fluid
leading to the hypothesis that HCV may cross the blood brain
barrier by infected monocytes which could result in secondary
infection of microglial cells [70]. It is well known that HCV can
activate the production of IFN-b through activation of the Toll-
like receptor system [71,72], which explains the strong upregula-
tion of IFN-b in the peripheral blood of HCV patients in our
study. Microarray studies have indicated that increased type I IFN
production occurs also in the livers of HCV-infected chimpanzees
and humans [73,74]. Therefore, we hypothesize that this
endogenous IFN production may, at least in part, explain the
depressive and cognitive disorders that are frequently seen in these
patients.
Only little is known about the relevance of the IFN system for
depressive episodes in the course of affective disorders. In
accordance with our mRNA data, it has been shown that plasma
levels of IFN-c are higher in patients with depression [75]. Though
Figure 2. Enhanced ISG expression and IFN-production in psychiatric patients with a severe depressive episode (SDE). Panel A. After
24 h of in vitro incubation without any further stimuli, total RNA was isolated from peripheral blood mononuclear cells of 11 healthy controls (‘‘co-N’’)
and 22 patients hospitalized for a SDE (‘‘co-D’’). Panel B. Total RNA was isolated directly from unseparated peripheral blood of healthy controls (‘‘co-
N’’, n=11), SDE patients (‘‘co-D, n=22’’) and HCV patients without (‘‘HCV-N’’, n=11) or with (‘‘HCV-D’’, n=11) IFN-induced depression. Expression of
IFN stimulated genes (ISGs) and IFN-b was analyzed by quantitative RT-PCR. Data (copies per 100,000 copies of ACTB) are shown as box plots (range,
25% and 75% percentile, mean).
doi:10.1371/journal.pone.0038668.g002
Table 4. Basal expression of interferons and toll-like receptor
genes in individuals with or without depressive disorders.
Gene Peripheral blood
1
Controls (n=11) SDE-P (n=22) t-test
mean 6 SEM mean 6 SEM p value
IFNA1 5,0266530.5 6,3636357.9 0.04
IFNA2 274.9624.5 352.9624.8 0.05
IFNB1 585.0663.0 1,113679.5 0.0001
IFNG 26.564.7 59.5616.3 n.s.
TLR3 144.8623.5 112.8616.1 n.s.
TLR7 659.2658.89 690.16124.6 n.s.
TLR8 ,40.064.0 ,40.04.0 n.d.
1Data are shown as copies per 100,000 copies of ACTB.
Abbreviations: SDE-P = severe depression episode patients, SEM = standard
error of the mean, n.s. = not significant, n.d. = not determined.
doi:10.1371/journal.pone.0038668.t004
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reported that they may help sustain the chronic inflammatory
response promoting the recruitment of inflammatory monocytes
[76] which may be involved in the pathophysiology of the
depressive symptoms. In this context, our findings may point to
a direct implication of monocyte/macrophage activation by IFN-
a with an alteration of the tryptophan metabolism and the
subsequent neurotransmitter dysregulation through GCH1 modu-
lation.
According to our results, this study may have major implications
regarding a) the pathophysiology of IFN-induced depression, b)
the pathophysiology of depressive disorders and cognitive
dysfunctions in HCV patients and c) the relevance of the IFN
system for severe depressive episodes in psychiatric diseases. Still,
possible limitations regarding the relative small sample size, the
different medical treatment taken by some HCV and psychiatric
patients or comparison of related but not identical psychiatric
disorders must be considered. Our study design does not allow to
clearly differentiate the alterations solely related to interferon
therapy from another medication, drug or altered physiological
condition. This would be possible to resolve by studying only
patients without any previous psychiatric history and treatment,
but such a group would be too difficult to obtain due to the
demographic characteristics of HCV and psychiatric patients.
Thus, the conclusions presented here need to be confirmed in
independent larger cohorts. Nevertheless, this work provides
valuable information about the possible mechanisms underlying
depression and other cognitive dysfunctions affecting HCV
patients treated with the current standard therapy and, as a last
resort, giving the likelihood to try to prevent, mitigate or avoid
such side effects. Collectively, our results extend across two
completely different clinical scenarios to generate convergent data
that bridge the phenomenon of IFN-induced depression and
major depression and thereby provide a pathophysiologic mech-
anism of depressive disorders focused on the role of inflammatory
cytokines.
In conclusion, these data suggest that selective hyper-respon-
siveness to exogenous or endogenous type I IFNs may lead to the
development of depressive symptoms. This sheds new light on the
pathogenesis of IFN-induced and depressive episodes and could
ultimately lead to the discovery of novel therapeutic approaches to
treat these conditions.
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